MedTrace Logo

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists

NCT01722786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 272

Last updated 2020-07-16

No results posted yet for this study

Summary

Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are included in this registry, or during emergency operations.

Conditions

  • Severe Bleeding
  • Urgent Surgery

Sponsors & Collaborators

  • Johannes Gutenberg University Mainz

    collaborator OTHER

  • University Hospital Greifswald

    collaborator OTHER

  • University Hospital Dresden

    collaborator OTHER

  • University Hospital, Aachen

    collaborator OTHER

  • Goethe University

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    collaborator OTHER

  • Vivantes Netzwerk für Gesundheit GmbH

    collaborator OTHER

  • Ruhr University of Bochum

    collaborator OTHER

  • Technische Universität Dresden

    collaborator OTHER

  • Städtisches Klinikum Dresden-Friedrichstadt

    collaborator UNKNOWN

  • Cardioangiologisches Centrum Bethanien

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2018-06-30
Completion
2019-07-09

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01722786 on ClinicalTrials.gov